Clinical Trial: Expanded Access to ANG1005 for Individual Patients

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III

Brief Summary: This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Detailed Summary:
Sponsor: Angiochem Inc

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Angiochem Inc

Dates:
Date Received: April 27, 2016
Date Started:
Date Completion:
Last Updated: June 3, 2016
Last Verified: June 2016